Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × pasireotide × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 7 Thoracic 2 Gastrointestinal 2 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 NET 1 Myeloid 1 Lymphoid 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Peritoneal Neoplasms 1

Interventions

Paclitaxel 193 Carboplatin 183 Bevacizumab 113 Cisplatin 108 pembrolizumab 77 Gemcitabine 52 olaparib 47 Docetaxel 38 Topotecan 34 Radiotherapy 32 niraparib 31 Cyclophosphamide 31 liposomal doxorubicin 27 Taxes 27 Drug Therapy 24 Doxorubicin 24 Letrozole 23 Nivolumab 21 Etoposide 19 Albumin-Bound Paclitaxel 19 Oxaliplatin 18 apatinib 17 Hyperthermic Intraperitoneal Chemotherapy 17 Brachytherapy 17 durvalumab 16 dostarlimab 16 Magnetic Resonance Spectroscopy 16 lenvatinib 15 camrelizumab 15 atezolizumab 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04826432 2024-02-08

PASIREOCHIP

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Terminated

Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡